Malignant pleural mesothelioma: A single-center experience in Turkey

Basit Öğe Kaydı
dc.authoridMertsoylu, Huseyin/0000-0002-1932-9784
dc.authoridsezer, ahmet/0000-0002-6445-1439
dc.authoridOzyilkan, Ozgur/0000-0001-8825-4918
dc.authoridSumbul, Ahmet Taner/0000-0002-5573-906X
dc.contributor.authorSezer, Ahmet
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorAbali, Huseyin
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorOzyilkan, Ozgur
dc.date.accessioned2024-09-18T20:55:50Z
dc.date.available2024-09-18T20:55:50Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: Malignant pleural mesothelioma is a rare lethal malignancy caused by asbestos exposure. It is more frequently seen in certain regions in Turkey. In this retrospective study, we aimed to analyse demographic, clinical, and pathological data and treatment-related features in 54 patients. Material/ Methods: The study included 54 patients diagnosed with malignant mesothelioma that were followed and treated. Results: Of the 54 patients, 34 (55.6%) were male. The median age in men and women were 60.3 (38.2-77.2) and 65.8 (37.7-77.5) years, respectively. In 35 (64.8%), exposure to asbestosis was present. Epithelial type was found in 27 (50.0%), followed by mixed type in 7 (13.0%) patients, and in 20 (37.0%) patients the subtype could not be determined. The disease was staged as IV in 37 (68.5%) patients. In 28 patients (51.9%), it was right-sided and in 1 (1.9%) it was bilateral. The most frequent metastatic sites (in decreasing order) were lungs, mediastinum, diaphragm, liver, and thoracal wall. Of the 54 patients, 36 (66.6%) received 1st-line chemotherapy and 20 (37%) 2nd-line chemotherapy. Eighteen patients (33.3%) received radiotherapy; 11 (20.3%) with palliative intention and 7 (12.9%) with curative intention. Median overall survival (OS) was 12.03 months (95% CI 7.2-16.8). OS was not affected by sex (p=0.32), smoking history (p=0.51), alcohol consumption (p=0.36), family history (p=0.67), pleural effusion presence (p=0.80), operation (p=0.14), clinical stage (p=0.072), symptom at presentation (p=0.66), having mixed type histology (p=0.079), asbestos exposure (p= 0.06), and type of 1st-line chemotherapy (p=0.161). On the contrary, it may be positively affected by good ECOG PS (0-1) (p<0.01), age below 65 (p=0.03), left-sided disease (p=0.01), receiving chemotherapy (p<0.01), having unilateral pleural effusion (p=0.018), and type of 2nd-line chemotherapy (p=0.025). Conclusions: OS of our patients was better than that found in the literature, seeming to be positively affected by early stages, better ECOG PS, age below 65 years, left side involvement, and having second-line chemotherapy with cisplatin- gemcitabine or 3M. Overall treatment success seems to be comparable to what is currently expected.en_US
dc.identifier.endpage832en_US
dc.identifier.issn1643-3750
dc.identifier.pmid24842043en_US
dc.identifier.scopus2-s2.0-84901035109en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage825en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12068
dc.identifier.volume20en_US
dc.identifier.wosWOS:000337249000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherInt Scientific Information, Incen_US
dc.relation.ispartofMedical Science Monitoren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRisk Factorsen_US
dc.subjectOverall Survivalen_US
dc.subjectRisk Factorsen_US
dc.subjectMesotheliomaen_US
dc.subjectSurvival Rateen_US
dc.titleMalignant pleural mesothelioma: A single-center experience in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu